# EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

> **NCT05284747** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 6019 (actual)

## Conditions studied

- Cardiovascular Disease
- Myocardial Infarction
- Stroke
- Coronary Revascularization

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Routine Lipid Management

## Key facts

- **NCT ID:** NCT05284747
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-26
- **Primary completion:** 2027-05-29
- **Final completion:** 2027-05-29
- **Target enrollment:** 6019 (ACTUAL)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05284747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05284747, "EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05284747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*